COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), today announced that it has successfully completed enrollment in a Phase 2 clinical trial evaluating Prochymal (remestemcel-L) ...
COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today the expansion of its intellectual property protection around Prochymal® (remestemcel-L). The United States ...
JDRF Partners with Osiris on a Phase II Trial to Evaluate an Immunomodulatory Cell Therapy Product For Type 1 Diabetes New York, NY – October 25, 2007 – The Juvenile Diabetes Research Foundation ...
"OSIRIS-REx has been so successful because we continue to pay attention to the details." When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. It's the ...
COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for ...
What: C. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris Therapeutics, Inc. (Nasdaq:OSIR) will preside over the closing bell. Where: NASDAQ MarketSite - 4 Times Square - 43rd & ...
KIHEI, Hawaii — A capsule from a NASA spacecraft landed in the Utah desert Sept. 24, completing a seven-year mission to return samples from a near Earth asteroid. The sample return capsule from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results